Allergy Therapeutics plc has disclosed a public dealing disclosure by Panmure Gordon (UK) Limited, an exempt principal trader with recognized intermediary status. The disclosure is made in accordance with Rule 8.5 of the Takeover Code. The disclosure relates to dealings in the securities of Allergy Therapeutics plc on October 9, 2023. The exempt principal trader has made purchases and sales of the 0.1p ordinary shares of Allergy Therapeutics plc. The highest price per unit paid/received was 0.015p, and the lowest price per unit paid/received was also 0.015p.

The disclosure does not include any cash-settled derivative transactions or stock-settled derivative transactions. There are no indemnity or option arrangements, agreements, or understandings relating to relevant securities that may be an inducement to deal or refrain from dealing. Similarly, there are no agreements, arrangements, or understandings relating to options or derivatives. The disclosure was made on October 10, 2023, and the contact person for further information is Freddie Wooding, with a telephone number of +44 (0)20 7886 2969.

No further information or details about Allergy Therapeutics plc or its operations are provided in this news release.